Intrinsic value of AtriCure - ATRC

Previous Close

$31.90

  Intrinsic Value

$6.57

stock screener

  Rating & Target

str. sell

-79%

Previous close

$31.90

 
Intrinsic value

$6.57

 
Up/down potential

-79%

 
Rating

str. sell

We calculate the intrinsic value of ATRC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  14.50
  13.55
  12.70
  11.93
  11.23
  10.61
  10.05
  9.54
  9.09
  8.68
  8.31
  7.98
  7.68
  7.41
  7.17
  6.96
  6.76
  6.58
  6.43
  6.28
  6.15
  6.04
  5.94
  5.84
  5.76
  5.68
  5.61
  5.55
  5.50
  5.45
Revenue, $m
  200
  227
  256
  287
  319
  353
  388
  425
  464
  504
  546
  589
  635
  682
  730
  781
  834
  889
  946
  1,006
  1,068
  1,132
  1,199
  1,269
  1,342
  1,419
  1,498
  1,581
  1,668
  1,759
Variable operating expenses, $m
  133
  148
  165
  183
  202
  222
  242
  264
  287
  310
  319
  345
  371
  399
  427
  457
  488
  520
  553
  588
  624
  662
  701
  742
  785
  829
  876
  925
  975
  1,029
Fixed operating expenses, $m
  85
  87
  89
  91
  93
  95
  97
  99
  101
  103
  105
  108
  110
  113
  115
  118
  120
  123
  126
  128
  131
  134
  137
  140
  143
  146
  149
  153
  156
  159
Total operating expenses, $m
  218
  235
  254
  274
  295
  317
  339
  363
  388
  413
  424
  453
  481
  512
  542
  575
  608
  643
  679
  716
  755
  796
  838
  882
  928
  975
  1,025
  1,078
  1,131
  1,188
Operating income, $m
  -17
  -8
  2
  13
  24
  36
  49
  62
  76
  90
  121
  137
  153
  171
  188
  207
  226
  246
  267
  289
  312
  336
  361
  387
  414
  443
  473
  504
  537
  571
EBITDA, $m
  4
  15
  25
  37
  49
  62
  76
  91
  106
  121
  138
  155
  173
  191
  210
  231
  251
  273
  296
  320
  344
  370
  397
  426
  455
  486
  518
  552
  587
  624
Interest expense (income), $m
  2
  2
  3
  4
  5
  6
  8
  9
  10
  12
  13
  14
  16
  18
  19
  21
  23
  25
  27
  29
  31
  33
  35
  38
  40
  43
  45
  48
  51
  54
  58
Earnings before tax, $m
  -20
  -11
  -2
  8
  18
  29
  40
  52
  64
  77
  107
  121
  136
  151
  167
  184
  202
  220
  239
  259
  279
  301
  323
  347
  372
  397
  425
  453
  483
  514
Tax expense, $m
  0
  0
  0
  2
  5
  8
  11
  14
  17
  21
  29
  33
  37
  41
  45
  50
  54
  59
  64
  70
  75
  81
  87
  94
  100
  107
  115
  122
  130
  139
Net income, $m
  -20
  -11
  -2
  6
  13
  21
  29
  38
  47
  57
  78
  88
  99
  110
  122
  134
  147
  160
  174
  189
  204
  220
  236
  253
  271
  290
  310
  331
  352
  375

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  303
  344
  387
  433
  482
  533
  587
  643
  701
  762
  826
  891
  960
  1,031
  1,105
  1,182
  1,262
  1,345
  1,431
  1,521
  1,615
  1,713
  1,814
  1,920
  2,031
  2,146
  2,267
  2,392
  2,524
  2,661
Adjusted assets (=assets-cash), $m
  303
  344
  387
  433
  482
  533
  587
  643
  701
  762
  826
  891
  960
  1,031
  1,105
  1,182
  1,262
  1,345
  1,431
  1,521
  1,615
  1,713
  1,814
  1,920
  2,031
  2,146
  2,267
  2,392
  2,524
  2,661
Revenue / Adjusted assets
  0.660
  0.660
  0.661
  0.663
  0.662
  0.662
  0.661
  0.661
  0.662
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
  0.661
Average production assets, $m
  123
  140
  158
  176
  196
  217
  239
  262
  286
  310
  336
  363
  391
  420
  450
  481
  514
  548
  583
  619
  658
  697
  739
  782
  827
  874
  923
  974
  1,028
  1,084
Working capital, $m
  19
  21
  24
  27
  30
  33
  36
  40
  44
  47
  51
  55
  60
  64
  69
  73
  78
  84
  89
  95
  100
  106
  113
  119
  126
  133
  141
  149
  157
  165
Total debt, $m
  53
  69
  87
  105
  125
  145
  167
  189
  213
  237
  263
  289
  316
  345
  375
  405
  437
  471
  505
  542
  579
  618
  659
  701
  746
  792
  840
  891
  944
  999
Total liabilities, $m
  121
  138
  155
  174
  193
  214
  235
  258
  281
  306
  331
  357
  385
  413
  443
  474
  506
  539
  574
  610
  648
  687
  727
  770
  814
  861
  909
  959
  1,012
  1,067
Total equity, $m
  181
  206
  232
  260
  289
  319
  352
  385
  420
  457
  495
  534
  575
  618
  662
  708
  756
  806
  857
  911
  967
  1,026
  1,087
  1,150
  1,216
  1,286
  1,358
  1,433
  1,512
  1,594
Total liabilities and equity, $m
  302
  344
  387
  434
  482
  533
  587
  643
  701
  763
  826
  891
  960
  1,031
  1,105
  1,182
  1,262
  1,345
  1,431
  1,521
  1,615
  1,713
  1,814
  1,920
  2,030
  2,147
  2,267
  2,392
  2,524
  2,661
Debt-to-equity ratio
  0.290
  0.340
  0.370
  0.410
  0.430
  0.450
  0.470
  0.490
  0.510
  0.520
  0.530
  0.540
  0.550
  0.560
  0.570
  0.570
  0.580
  0.580
  0.590
  0.590
  0.600
  0.600
  0.610
  0.610
  0.610
  0.620
  0.620
  0.620
  0.620
  0.630
Adjusted equity ratio
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -20
  -11
  -2
  6
  13
  21
  29
  38
  47
  57
  78
  88
  99
  110
  122
  134
  147
  160
  174
  189
  204
  220
  236
  253
  271
  290
  310
  331
  352
  375
Depreciation, amort., depletion, $m
  22
  22
  23
  24
  25
  26
  27
  28
  30
  31
  16
  18
  19
  21
  22
  24
  25
  27
  29
  30
  32
  34
  36
  38
  41
  43
  45
  48
  50
  53
Funds from operations, $m
  2
  11
  21
  30
  38
  47
  57
  66
  77
  87
  94
  106
  118
  131
  144
  158
  172
  187
  203
  219
  236
  254
  272
  292
  312
  333
  355
  378
  403
  428
Change in working capital, $m
  2
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  7
  8
  8
  9
Cash from operations, $m
  0
  9
  19
  27
  35
  44
  53
  63
  73
  84
  90
  102
  114
  127
  140
  153
  167
  182
  197
  214
  230
  248
  266
  285
  305
  326
  348
  371
  394
  420
Maintenance CAPEX, $m
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -18
  -19
  -21
  -22
  -24
  -25
  -27
  -29
  -30
  -32
  -34
  -36
  -38
  -41
  -43
  -45
  -48
  -50
New CAPEX, $m
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
  -35
  -37
  -38
  -40
  -41
  -43
  -45
  -47
  -49
  -51
  -54
  -56
Cash from investing activities, $m
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -41
  -43
  -46
  -48
  -51
  -53
  -57
  -59
  -62
  -66
  -68
  -72
  -75
  -79
  -83
  -88
  -92
  -96
  -102
  -106
Free cash flow, $m
  -21
  -14
  -6
  0
  7
  14
  21
  28
  36
  45
  49
  59
  68
  78
  89
  100
  111
  123
  135
  148
  162
  176
  190
  206
  222
  238
  256
  274
  293
  313
Issuance/(repayment) of debt, $m
  15
  16
  17
  19
  20
  21
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  32
  33
  35
  36
  38
  39
  41
  43
  44
  46
  48
  50
  53
  55
Issuance/(repurchase) of shares, $m
  42
  36
  28
  22
  16
  10
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  57
  52
  45
  41
  36
  31
  24
  22
  23
  24
  25
  26
  27
  29
  30
  31
  32
  33
  35
  36
  38
  39
  41
  43
  44
  46
  48
  50
  53
  55
Total cash flow (excl. dividends), $m
  36
  38
  40
  41
  42
  44
  45
  51
  60
  69
  75
  85
  96
  107
  119
  131
  143
  156
  170
  184
  199
  215
  231
  248
  266
  285
  304
  324
  346
  368
Retained Cash Flow (-), $m
  -42
  -36
  -28
  -28
  -29
  -31
  -32
  -34
  -35
  -36
  -38
  -39
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -61
  -63
  -66
  -69
  -72
  -75
  -79
  -82
Prev. year cash balance distribution, $m
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -3
  2
  11
  13
  13
  13
  13
  17
  25
  33
  37
  46
  55
  64
  74
  85
  95
  107
  118
  131
  143
  156
  170
  185
  200
  215
  232
  249
  267
  286
Discount rate, %
  5.70
  5.99
  6.28
  6.60
  6.93
  7.27
  7.64
  8.02
  8.42
  8.84
  9.28
  9.75
  10.24
  10.75
  11.29
  11.85
  12.44
  13.06
  13.72
  14.40
  15.12
  15.88
  16.67
  17.51
  18.38
  19.30
  20.27
  21.28
  22.34
  23.46
PV of cash for distribution, $m
  -3
  2
  9
  10
  9
  9
  8
  9
  12
  14
  14
  15
  15
  15
  15
  14
  13
  12
  10
  9
  7
  6
  5
  4
  3
  2
  2
  1
  1
  1
Current shareholders' claim on cash, %
  96.1
  93.3
  91.4
  90.1
  89.2
  88.7
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6
  88.6

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

FINANCIAL RATIOS  of  AtriCure (ATRC)

Valuation Ratios
P/E Ratio -32.2
Price to Sales 6.9
Price to Book 6.3
Price to Tangible Book
Price to Cash Flow -70.9
Price to Free Cash Flow -46.2
Growth Rates
Sales Growth Rate 19.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -38.5%
Cap. Spend. - 3 Yr. Gr. Rate 21.7%
Financial Strength
Quick Ratio 22
Current Ratio 0.1
LT Debt to Equity 22%
Total Debt to Equity 23.2%
Interest Coverage -16
Management Effectiveness
Return On Assets -11.3%
Ret/ On Assets - 3 Yr. Avg. -11.9%
Return On Total Capital -16.2%
Ret/ On T. Cap. - 3 Yr. Avg. -15.7%
Return On Equity -18.6%
Return On Equity - 3 Yr. Avg. -17%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 71.6%
Gross Margin - 3 Yr. Avg. 71.4%
EBITDA Margin -13.5%
EBITDA Margin - 3 Yr. Avg. -13.6%
Operating Margin -20%
Oper. Margin - 3 Yr. Avg. -18.6%
Pre-Tax Margin -21.3%
Pre-Tax Margin - 3 Yr. Avg. -19%
Net Profit Margin -21.3%
Net Profit Margin - 3 Yr. Avg. -19%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ATRC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ATRC stock intrinsic value calculation we used $174.716 million for the last fiscal year's total revenue generated by AtriCure. The default revenue input number comes from 0001 income statement of AtriCure. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ATRC stock valuation model: a) initial revenue growth rate of 14.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.7%, whose default value for ATRC is calculated based on our internal credit rating of AtriCure, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of AtriCure.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ATRC stock the variable cost ratio is equal to 67.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $83 million in the base year in the intrinsic value calculation for ATRC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.1% for AtriCure.

Corporate tax rate of 27% is the nominal tax rate for AtriCure. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ATRC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ATRC are equal to 61.6%.

Life of production assets of 20.4 years is the average useful life of capital assets used in AtriCure operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ATRC is equal to 9.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $161.166 million for AtriCure - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.094 million for AtriCure is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of AtriCure at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
BSX Boston Scienti 36.47 12.09  str.sell
MMSI Merit Medical 59.10 1.24  str.sell
ABMD Abiomed 320.78 278.50  sell
EW Edwards Lifesc 153.12 121.67  hold
TFX Teleflex 260.66 204.28  hold

COMPANY NEWS

▶ AtriCure: 3Q Earnings Snapshot   [05:30PM  Associated Press]
▶ AtriCure to Participate in Upcoming Investor Conferences   [Oct-22-18 04:01PM  Business Wire]
▶ Is AtriCure Inc (NASDAQ:ATRC) A Financially Sound Company?   [Oct-16-18 02:12PM  Simply Wall St.]
▶ AtriCure to Announce Third Quarter 2018 Financial Results   [Oct-11-18 08:00AM  Business Wire]
▶ These Cincinnati stocks took the biggest hit amid Dows worst loss since February   [Oct-10-18 05:20PM  American City Business Journals]
▶ AtriCure: 2Q Earnings Snapshot   [05:38PM  Associated Press]
▶ AtriCure Made an Important Upside Breakout   [Jul-20-18 12:50PM  TheStreet.com]
▶ AtriCure to Announce Second Quarter 2018 Financial Results   [Jul-11-18 08:00AM  Business Wire]
▶ The List: Dayton-Area Public Company Executive Compensation   [Jul-02-18 05:16AM  American City Business Journals]
▶ AtriCure stock hits 52-week high   [Jun-15-18 02:44PM  American City Business Journals]
▶ AtriCure Announces 2018 Analyst and Investor Meeting   [Jun-12-18 08:00AM  Business Wire]
▶ The List: Dayton-Area Top 100 Companies   [Jun-01-18 08:15AM  American City Business Journals]
▶ 7 Greater Cincinnati firms among Ohio's 30 top-paying companies: SLIDESHOW   [May-31-18 01:19PM  American City Business Journals]
▶ These are Ohio's 30 top paying companies (Countdown)   [May-30-18 04:21PM  American City Business Journals]
▶ These Cincinnati public companies pay their employees the most: SLIDESHOW   [May-08-18 02:40PM  American City Business Journals]
▶ Here's why AtriCure stock is surging   [12:26PM  American City Business Journals]
▶ AtriCure: 1Q Earnings Snapshot   [Apr-26-18 06:11PM  Associated Press]
▶ Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?   [Apr-10-18 03:19PM  Simply Wall St.]
▶ AtriCure to Announce First Quarter 2018 Financial Results   [Apr-05-18 08:00AM  Business Wire]
▶ AtriCure reports 4Q loss   [Feb-26-18 05:36PM  Associated Press]
▶ AtriCure, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ AtriCure Q4 Earnings Outlook   [11:27AM  Benzinga]
▶ Cincinnati medical device maker gets board refresh   [Feb-20-18 05:01PM  American City Business Journals]
▶ AtriCure Names Scott Drake Board Chairman   [08:00AM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : December 11, 2017   [Dec-11-17 01:31PM  Capital Cube]
▶ ETFs with exposure to AtriCure, Inc. : December 1, 2017   [Dec-01-17 10:26AM  Capital Cube]
▶ ETFs with exposure to AtriCure, Inc. : November 20, 2017   [Nov-20-17 11:41AM  Capital Cube]
▶ ETFs with exposure to AtriCure, Inc. : November 8, 2017   [Nov-08-17 05:37PM  Capital Cube]
▶ AtriCure reports 3Q loss   [Nov-01-17 05:33PM  Associated Press]
▶ AtriCure to Present at the Stifel Healthcare Conference   [Oct-20-17 08:00AM  Business Wire]
▶ AtriCure to Announce Third Quarter 2017 Financial Results   [Oct-10-17 08:00AM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : August 15, 2017   [Aug-15-17 03:22PM  Capital Cube]
▶ Stock surge on Wall Street pushes these 25 S&P 500 stocks to record highs   [Aug-04-17 07:47AM  American City Business Journals]
▶ AtriCure reports 2Q loss   [Jul-27-17 11:57PM  Associated Press]
▶ AtriCure Announces Hiring of Chief Technology Officer   [Jul-18-17 04:15PM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : July 13, 2017   [Jul-13-17 03:30PM  Capital Cube]
▶ AtriCure to Announce Second Quarter 2017 Financial Results   [Jul-06-17 08:00AM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : May 12, 2017   [May-12-17 03:40PM  Capital Cube]
▶ Here's Why ArtiCure, Inc. Is Up Double-Digits Today   [May-05-17 12:49PM  Motley Fool]
▶ AtriCure reports 1Q loss   [May-04-17 06:33PM  Associated Press]
▶ AtriCure to Announce First Quarter 2017 Financial Results   [Apr-07-17 04:05PM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : April 5, 2017   [Apr-05-17 04:21PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.